RT Journal Article
SR Electronic
T1 Cervical cancer screening improvements with self-sampling during the COVID-19 pandemic
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.19.22277806
DO 10.1101/2022.07.19.22277806
A1 Elfström, K. Miriam
A1 Dillner, Joakim
YR 2022
UL http://medrxiv.org/content/early/2022/07/23/2022.07.19.22277806.abstract
AB Background At the onset of the COVID-19 pandemic cervical screening in the capital region of Sweden was cancelled for several months. A series of measures to preserve and improve the cervical screening under the circumstances were instituted, including a switch to screening with HPV self-sampling to enable screening in compliance with social distancing recommendations.Methods We describe the major changes implemented, which were i) nationwide implementation of HPV screening ii) switch to primary self-sampling instead of clinician sampling iii) implementation of HPV screening in all screening ages and iv) combined HPV vaccination and HPV screening in the cervical screening program.Results A temporary government regulation allowed primary self-sampling with HPV screening in all ages. In the Stockholm region, 330,000 self-sampling kits were sent to the home address of screening-eligible women, instead of an invitation to clinician sampling. An increase in population test coverage was seen (from 66% to 70% in just one year). In addition, a national campaign for faster elimination of cervical cancer with concomitant screening and vaccination for women in ages 23-28 was launched.Conclusions The COVID-19 pandemic necessitated major changes in the cervical cancer preventive strategies, where it can already be concluded that the strategy with organised primary self-sampling for HPV has resulted in a major improvement of population test-coverage.Funding Funded by the Swedish Association of Local Authorities and Regions, the Swedish Cancer Society, the European Union’s Horizon 2020 Research and Innovation Program, the Swedish government and the Stockholm county.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study is not a clinical trial.Funding StatementThe work of the Swedish National Cervical Screening registry was supported by the Swedish Association of Local Authorities and Regions and the Swedish Cancer Society (20 1199 UsF 02 H). Miriam Elfström and Joakim Dillner are supported by the European Union's Horizon 2020 Research and Innovation Program, RISCC under grant agreement No. 847845. The Swedish even faster campaign is supported by the Swedish government and by the Stockholm county. The funding agencies have had no role in the design, execution, or interpretation of the study or in the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The publication of official statistics by the National Cervical Screening Registry is supported by these ethical permissions: Swedish Ethical Review Authority. Ref numbers: 2019-03166 and 2020-05929.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableThe data in this report derives from publicly available data on new Swedish regulations and strategies used during the pandemic (major official websites www.socialstyrelsen.se and www.regeringen.se ). Results on population coverage and number of screening invitations/self-sampling kits sent are derived from the website of the Swedish National Cervical Screening Registry of Sweden (www.nkcx.se).